In the twenties

CD27 agonists help myeloid cells chow down on cancer

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing the strategy in the clinic with an anti-CD20 mAb.

Author Sean Lim told BioCentury that while CD27 is primarily known for its co-stimulatory activity on T cells, the target’s

Read the full 633 word article

User Sign In